Print Share

Drugs for leukemia and other cancers, and potential therapies for gout and malaria

Institution:

Albert Einstein College of Medicine

Researchers:

Vern L. Schramm, PhD, professor of biochemistry and Ruth Merns Chair in Biochemistry at Albert Einstein College of Medicine

Impact:

Dr. Schramm and his collaborators have developed synthetic compounds based on transition-state inhibitors, which prevent enzymatic reactions. They have developed drugs to treat leukemia and gout, which have moved into clinical trials, and to develop antibiotics that don’t trigger resistance. This knowledge also permits drug design for other disorders.

Timeline:

2009 to present

Topics

AgingBasic ScienceCancerCardiovascularClinical ResearchDiagnosticsDrug DevelopmentFeaturedGeneticsImmune SystemInfectious DiseaseMedical DeviceMental HealthNeurodegenerativeNobel PrizePediatricsPublic HealthRespiratorySurgical AdvancementTechnologyTreatment AdvancesVaccines

Schools

Albany Medical CollegeAlbert Einstein College of MedicineCity University of New York School of MedicineColumbia University College Of Physicians and SurgeonsHofstra Northwell School of Medicine at Hofstra UniversityIcahn School of Medicine at Mount SinaiJacobs School of Medicine and Biomedical Sciences, the University at BuffaloNew York Institute of Technology College of Osteopathic MedicineNew York Medical CollegeNew York University School of MedicineSchool of Medicine and Dentistry at the University of Rochester Medical CenterStony Brook University School of MedicineSUNY Downstate Medical CenterSUNY Upstate Medical UniversityTouro College of Osteopathic MedicineWeill Cornell MedicineWeill Cornell Medicine, NewYork-Presbyterian